Restoration of the health system must not neglect medicines – but who has the power of reform?

References

[1]  Department of the Prime Minister and Cabinet. Health and Disability Review Transition Unit. Response to Health and Disability System Review. The new health system. [cited 2021 May 24]. Available from: https://dpmc.govt.nz/our-business-units/transition-unit/response-health-and-disability-system-review/information

[2]  Waitangi Tribunal. Wai 2575 – the Health Services and Outcomes Inquiry. [cited 2021 May 24]. Available from: https://waitangitribunal.govt.nz/inquiries/kaupapa-inquiries/health-services-and-outcomes-inquiry/

[3]  Waitangi Tribunal. A Guide to the Principles of the Treaty of Waitangi as expressed by the Courts and the Waitangi Tribunal. [cited 2021 May 24]. Available from: https://waitangitribunal.govt.nz/assets/Documents/Publications/WT-Principles-of-the-Treaty-of-Waitangi-as-expressed-by-the-Courts-and-the-Waitangi-Tribunal.pdf

[4]  Jackson M. Decolonisation and the stories in the land. E-Tangata. 9 May 2021. [cited 2021 May 24]. Available from: https://e-tangata.co.nz/comment-and-analysis/moana-jackson-decolonisation-and-the-stories-in-the-land/

[5]  Health Quality & Safety Commission. 2019. He matapihi ki te kounga o ngā manaakitanga ā-hauora o Aotearoa 2019 – he tirohanga ki te ōritenga hauora o te Māori | A window on the quality of Aotearoa New Zealand’s health care 2019 – a view on Māori health equity. Wellington: Health Quality & Safety Commission. [cited 2021 May 10]. Available from: https://www.hqsc.govt.nz/assets/Health-Quality-Evaluation/PR/Window_2019_web_final.pdf

[6]  Recipe for resilience: Te ao Māori and the Covid-19 response. The Spin Off. 5 November 2020. [cited 2021 May 25]. Available from: https://thespinoff.co.nz/partner/health-quality-and-safety-commission/05-11-2020/recipe-for-resilience-te-ao-maori-and-the-covid-19-response/

[7]  Metcalfe S, Beyene K, Urlich J, et al. Te Wero tonu – the challenge continues: Māori access to medicines 2006/07–2012/13 update. N Z Med J. 2018; 131 27–47.

[8]  Webb R, Wilson N. Rheumatic fever in New Zealand. J Paediatr Child Health. 2013; 49 179–84.
| Rheumatic fever in New Zealand.Crossref | GoogleScholarGoogle Scholar |

[9]  de Boer S, Lewis CA, Fergusson W, et al. Ethnicity, socioeconomic status and the severity and course of non-cystic fibrosis bronchiectasis. Intern Med J. 2018; 48 845–50.
| Ethnicity, socioeconomic status and the severity and course of non-cystic fibrosis bronchiectasis.Crossref | GoogleScholarGoogle Scholar |

[10]  Bibby S, Milne R, Beasley R. Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand. N Z Med J. 2015; 128 30–8.

[11]  O’Sullivan C, Baker MG, Zhang J, et al. The epidemiology of serious skin infections in New Zealand children: comparing the Tairawhiti region with national trends. N Z Med J. 2012; 125 40–54.

[12]  Metcalfe S, Bhawan S, Vallabh M, et al. Over and under? Ethnic inequities in community antibacterial prescribing. N Z Med J. 2019; 132 65–8.

[13]  Baker MG, Barnard LT, Kvalsvig A, et al. Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet. 2012; 379 1112–9.
| Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study.Crossref | GoogleScholarGoogle Scholar |

[14]  Auckland UniServices. Variation in medicines use by ethnicity: a comparison between 2006/7 and 2012/13. Final Report. Prepared for PHARMAC. Auckland: University of Auckland, 2018. [cited 2021 May 25]. Available from: http://www.pharmac.govt.nz/assets/2018-01-19-Variation-in-medicines-use-by-ethnicity-Final-Report.pdf; Appendices and data: http://www.pharmac.govt.nz/assets/2018-02-26-Maori-uptake-of-medicines-appendices.xlsx

[15]  Te Karu L, Kenealy T, Bryant L, et al. “I just wanted to close myself off and die.” The long shadow of inequity for Māori with gout. MAI Journal. 2020; 9 152–65.

[16]  Dalbeth N, Gow P, Jackson G, et al. Gout in Aotearoa New Zealand: are we going to ignore this for another 3 years? N Z Med J. 2016; 129 10–3.

[17]  Dalbeth N, Dowell T, Gerard C, et al. Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. N Z Med J. 2018; 131 8–12.

[18]  Guillén AG, Te Karu L, Singh JA, Dalbeth N. Gender and Ethnic Inequities in Gout Burden and Management. Rheum Dis Clin North Am. 2020; 46 693–703.
| Gender and Ethnic Inequities in Gout Burden and Management.Crossref | GoogleScholarGoogle Scholar |

[19]  Te Karu L, Harwood M, Bryant L, et al. Compounding inequity: a qualitative study of gout management in an urban marae clinic in Auckland. J Prim Health Care. 2021; 13 27–35.
| Compounding inequity: a qualitative study of gout management in an urban marae clinic in Auckland.Crossref | GoogleScholarGoogle Scholar |

[20]  Te Karu L, Bryant L, Elley CR. Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study. J Prim Health Care. 2013; 5 214–22.
| Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study.Crossref | GoogleScholarGoogle Scholar |

[21]  Te Karu L, Bryant L, Harwood M, Arroll B. Pounamu: Achieving health equity in Aotearoa New Zealand: the contribution of medicines optimisation. J Prim Health Care. 2018; 10 11–5.
| Pounamu: Achieving health equity in Aotearoa New Zealand: the contribution of medicines optimisation.Crossref | GoogleScholarGoogle Scholar |

[22]  Health Quality & Safety Commission. Atlas of Healthcare Variation. Gout. [cited 2021 May 10]. Available from: https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/gout/

[23]  Tomlin A, Woods DJ, Lambie A, et al. Ethnic inequality in non-steroidal anti-inflammatory drug-associated harm in New Zealand: A national population-based cohort study. Pharmacoepidemiol Drug Saf. 2020; 29 881–9.
| Ethnic inequality in non-steroidal anti-inflammatory drug-associated harm in New Zealand: A national population-based cohort study.Crossref | GoogleScholarGoogle Scholar |

[24]  Norris P, Tordoff J, McIntosh B, et al. Impact of prescription charges on people living in poverty: A qualitative study. Res Social Adm Pharm. 2016; 12 893–902.
| Impact of prescription charges on people living in poverty: A qualitative study.Crossref | GoogleScholarGoogle Scholar |

[25]  Health Quality & Safety Commission. Atlas of Healthcare Variation. Health service access. [cited 2021 May 25]. Available from: https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/health-service-access/

[26]  Ministry of Health. 2020. Annual Data Explorer 2019/20: New Zealand Health Survey [Data File]. [cited 2021 May 25]. Available from: https://minhealthnz.shinyapps.io/nz-health-survey-2019-20-annual-data-explorer/

[27]  Martini ND, van der Werf B, Bassett-Clarke D. Primary medication non-adherence at Counties Manukau Health Emergency Department (CMH-ED), New Zealand: an observational study. BMJ Open. 2020; 10 e035775
| Primary medication non-adherence at Counties Manukau Health Emergency Department (CMH-ED), New Zealand: an observational study.Crossref | GoogleScholarGoogle Scholar |

[28]  Goodyear-Smith F, Ashton T. New Zealand health system: universalism struggles with persisting inequities. Lancet. 2019; 394 432–42.
| New Zealand health system: universalism struggles with persisting inequities.Crossref | GoogleScholarGoogle Scholar |

[29]  McGinn O, Fulcher HJ, Arroll B, McCowan L. Barriers to the prescription of LARCs in general practice in New Zealand – a qualitative research study. N Z Med J. 2019; 132 63–9.

[30]  Glover M, Kira A, Johnston V, et al. A systematic review of barriers and facilitators to participation in randomized controlled trials by Indigenous people from New Zealand, Australia, Canada and the United States. Glob Health Promot. 2015; 22 21–31.
| A systematic review of barriers and facilitators to participation in randomized controlled trials by Indigenous people from New Zealand, Australia, Canada and the United States.Crossref | GoogleScholarGoogle Scholar |

[31]  Tai V, Merriman TR, Dalbeth N. Genetic advances in gout: potential applications in clinical practice. Curr Opin Rheumatol. 2019; 31 144–51.
| Genetic advances in gout: potential applications in clinical practice.Crossref | GoogleScholarGoogle Scholar |

[32]  Watson L, Roddy E. The role of diet in serum urate concentration. BMJ. 2018; 363 k4140
| The role of diet in serum urate concentration.Crossref | GoogleScholarGoogle Scholar |

[33]  Parliamentary Counsel Office. Medicines Act 1981. [cited 2021 May 25]. Available from: https://www.legislation.govt.nz/act/public/1981/0118/latest/DLM53790.html

[34]  Parliamentary Counsel Office. Medicines Regulations 1984. [cited 2021 May 25]. Available from: https://www.legislation.govt.nz/regulation/public/1984/0143/latest/DLM95668.html

[35]  Health Navigator. Rongoā Māori. https://www.healthnavigator.org.nz/health-a-z/r/rongoā-māori/ (accessed 31/05/2021).

[36]  Ministry of Health. 2015. Implementing Medicines New Zealand 2015 to 2020. Wellington: Ministry of Health. [cited 2021 May 31]. Available from: https://www.health.govt.nz/publication/implementing-medicines-new-zealand-2015-2020

[37]  Came H, O’Sullivan D, McCreanor T. Introducing critical Tiriti policy analysis through a retrospective review of the New Zealand Primary Health Care Strategy. Ethnicities. 2020; 20 434–56.
| Introducing critical Tiriti policy analysis through a retrospective review of the New Zealand Primary Health Care Strategy.Crossref | GoogleScholarGoogle Scholar |

[38]  Robb G, Loe E, Maharaj A, et al. Medication-related patient harm in New Zealand hospitals. N Z Med J. 2017; 130 21–32.